×

NanoString Technologies to Present at Two Upcoming Healthcare Conferences

SEATTLE, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at two upcoming conferences in September. Presenting at the conferences will be Brad Gray, Chief Executive Officer.

Brad Gray, President and Chief Executive Officer, is scheduled to present at the Baird 2016 Global Healthcare Conference in New York, NY on Wednesday, September 7, 2016 at 12:45pm PT (3:45pm ET).

Mr. Gray is also scheduled to present at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2016 at 6:55am PT (9:55am ET).

Interested parties can access a live webcast of both presentations on the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentations and archived for 90 days.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,200 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications dfarrell@nanostring.com Phone: 206-602-1768

Source:NanoString Technologies

More From Press Releases